| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.23 | 5e-05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.21 | 5e-05 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0006 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.15 | 0.005 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |